Physician profile
Ingrid A Mayer
NPI 1871677971
$94,193.42
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $25K · 2021: $26K.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19,014.62 | 2019-2020 | |
| Novartis Pharma Ag | $12,364.27 | 2019-2021 | |
| Genzyme Corporation | $10,388.00 | 2021 | |
| Eli Lilly and Company | $10,227.29 | 2019-2022 | |
| Astrazeneca Uk Limited | $8,562.50 | 2020-2021 | |
| Immunomedics, INC. | $5,225.00 | 2020 | |
| Daiichi Sankyo INC. | $5,137.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $4,992.75 | 2019 | |
| Lilly USA, LLC | $3,500.00 | 2020 | |
| Merck Sharp & Dohme LLC | $3,500.00 | 2021 | |
| Pfizer INC. | $2,982.30 | 2019-2020 | |
| Seagen INC. | $2,628.95 | 2019 | |
| Eisai INC. | $1,718.75 | 2020 | |
| Macrogenics, INC. | $1,500.00 | 2021 | |
| Blueprint Medicines Corporation | $1,400.00 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $990.00 | 2021 | |
| Puma Biotechnology, INC. | $49.77 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$7,777.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.